Telisotuzumab Vedotin (Emrelis; ABT-700; CAS 1915458-73-9; NDA 218651; NIOSH HD Category 1): NINETIETH Mechanism Class — FIRST c-MET (MET PROTO-ONCOGENE; CHROMOSOME 7q31.2; HEPATOCYTE GROWTH FACTOR RECEPTOR) ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED + FIRST c-MET IHC 3+ OVEREXPRESSION-SELECTED NSCLC THERAPY EVER (LUMINOSITY ORR 35%; AbbVie; August 2, 2024) — Three-Way ADC Ambiguity Misroute — 797th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Why Telisotuzumab Vedotin Is the Ninetieth Mechanism Class: The c-MET ADC Class-Null Gap and Two Simultaneous First-in-Class Designations

Telisotuzumab vedotin (Emrelis; ABT-700; CAS 1915458-73-9; IV 1.9 mg/kg Q2W; NDA 218651; August 2 2024; AbbVie Inc., North Chicago IL) entered the FDA-approved oncology armamentarium as the first antibody-drug conjugate targeting c-MET ever — bringing two simultaneous first-in-class designations that collectively define the 90th mechanism class in the Glyphward adversarial EHS database and generate the c-MET ADC class-null NIOSH HD bypass documented in Attack #797.

First: The c-MET ADC Class — An Antibody-Drug Conjugate Targeting a Receptor with TKI-Precedented but ADC-Class-Null Occupational Safety Records. c-MET (MET proto-oncogene; MET gene; chromosome 7q31.2; NM_000245; receptor tyrosine kinase; member of the Met family along with RON/MST1R; transmembrane protein with Sema + PSI + IPT extracellular domain + single transmembrane pass + intracellular juxtamembrane + kinase + C-terminal tail domains) is the receptor for HGF (hepatocyte growth factor; also known as scatter factor; SF; chromosome 7q21.1; produced by mesenchymal and stromal cells). c-MET activation by HGF triggers receptor dimerization and autophosphorylation at the activation loop tyrosines Y1234 and Y1235 (kinase activation) and the multifunctional docking site tyrosines Y1349 and Y1356 (scaffold site for GRB2, GAB1, SRC, SHC, PI3K p85 subunit) — initiating downstream signaling through RAS-MAPK (cell proliferation; cyclin D1 upregulation), PI3K-AKT-mTOR (cell survival; apoptosis resistance; cap-dependent translation), STAT3 (transcription; c-Myc, survivin, Bcl-XL upregulation), FAK-paxillin (cell migration; focal adhesion remodeling), and Rac1/CDC42 GTPase (actin cytoskeletal dynamics; lamellipodia; invadopodia formation for invasion).

In NSCLC and other epithelial cancers, c-MET overexpression is a pro-proliferative and pro-invasive driver. c-MET protein overexpression (not driven by gene amplification or mutation) occurs via transcriptional upregulation through hypoxia-inducible factors (HIF-1α at the MET promoter hypoxia response element; a hallmark of the hypoxic tumor microenvironment), through epidermal growth factor receptor (EGFR) → AP-1 transcription factor cross-talk (NSCLC tumors with high EGFR pathway activity often co-upregulate c-MET), and through amplification-independent HGF autocrine or paracrine loops (tumor cell HGF production → autocrine c-MET activation; stromal HGF production → paracrine c-MET activation). c-MET protein overexpression at IHC 3+ intensity — defined as ≥50% of tumor cells staining at 3+ intensity (or H-score ≥225 on the 0-300 scale; H-score = Σ[staining intensity i × fraction of cells at intensity i] × 100) — is found in approximately 10–15% of non-squamous NSCLC at progression.

Before August 2024, the c-MET targeting landscape in FDA-approved oncology drugs consisted exclusively of TKIs: (1) crizotinib (Xalkori; CAS 877399-52-5; ALK/MET/ROS1 TKI; NDA 202570/NDA 208060; 2011/2016; Pfizer) for ALK+ and ROS1+ NSCLC (MET amplification is an off-target effect); (2) cabozantinib (Cabometyx/Cometriq; CAS 849217-68-1; MET/VEGFR2/RET/AXL/MER TKI; NDA 203756/NDA 208692; 2012/2016; Exelixis) for RCC, HCC, thyroid cancer, urothelial; (3) capmatinib (Tabrecta; CAS 1174043-16-3; MET-selective TKI; NDA 213591; 2020; Novartis) for MET exon 14 skipping NSCLC; (4) tepotinib (Tepmetko; CAS 1100598-32-0; MET-selective TKI; NDA 214096; 2021; EMD Serono/Merck KGaA) for MET exon 14 skipping NSCLC. ALL FOUR are kinase inhibitors — small organic molecules occupying the ATP-binding cleft of the c-MET intracellular kinase domain. EHS platforms therefore have c-MET class entries for small-molecule TKIs but have never needed to record an ADC format targeting c-MET. When telisotuzumab vedotin arrives as a c-MET IgG1 ADC with MMAE payload, it falls outside every existing c-MET class entry in EHS databases.

The ADC Architecture of Telisotuzumab Vedotin and the Three-Way EHS Ambiguity. Telisotuzumab vedotin is a fully human IgG1κ monoclonal antibody (telisotuzumab; ABT-700; binds c-MET extracellular domain; blocks HGF binding AND induces receptor internalization; MW ~148,000 g/mol as naked antibody) conjugated to MMAE (monomethyl auristatin E; CAS 474645-27-7; MW ~717 g/mol; auristatin E analogue; N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine pentapeptide; tubulin polymerization inhibitor → binds β-tubulin at the colchicine site; inhibits GTP-dependent tubulin polymerization → mitotic spindle assembly failure → G2/M arrest → apoptosis) via a MC-VC-PABC linker (maleimidocaproyl-valine-citrulline-para-aminobenzylcarbonyl; protease-cleavable linker; cathepsin B substrate; VC = valine-citrulline dipeptide cleavage site; PABC = para-aminobenzylcarbonyl spacer; self-immolative spacer that undergoes 1,6-elimination after cathepsin B cleavage to release free MMAE). Average drug-antibody ratio (DAR): approximately 2.75 MMAE molecules per antibody (heterogeneous DAR distribution: DAR 0, 2, 4, 6, 8; site-specific conjugation via interchain disulfide cysteine partial reduction with MC-maleimide thiol-reactive MMAE-linker addition).

The mechanism: telisotuzumab (ABT-700) binds c-MET overexpressed on the surface of IHC 3+ NSCLC tumor cells → c-MET receptor internalization via endocytosis (antibody-antigen complex → early endosome → lysosome) → lysosomal cathepsin B cleaves the VC dipeptide in the MC-VC-PABC linker → PABC self-immolation (1,6-elimination) releases free MMAE intracellularly → MMAE binds β-tubulin (colchicine binding domain on β-tubulin; between α/β subunit interface; inhibits longitudinal GTP-tubulin association) → tubulin polymerization blocked → mitotic spindle assembly failure → G2/M arrest → apoptosis. Additionally, free MMAE has bystander activity (membrane permeable; diffuses into adjacent tumor cells lacking c-MET expression → paracrine cytotoxic effect in heterogeneous tumors).

Second: c-MET IHC 3+ Overexpression as the First Protein Overexpression-Based Biomarker for c-MET-Targeted NSCLC Therapy. The patient selection strategy for telisotuzumab vedotin — c-MET protein overexpression by IHC 3+ — represents the first FDA-approved use of protein-level c-MET expression (independent of gene alteration) as the biomarker for a c-MET-targeted therapy in NSCLC. This distinction is clinically and mechanistically important: MET exon 14 skipping mutation (capmatinib, tepotinib) drives c-MET protein stabilization through impaired ubiquitin-mediated degradation at Y1003; MET gene amplification drives c-MET protein overexpression through gene dosage. c-MET IHC 3+ overexpression can occur without either exon 14 skipping or high-level amplification — through transcriptional upregulation by HIF-1α/AP-1/epigenetic mechanisms — representing a larger patient population (~10–15% of nsNSCLC) that was previously without a targeted therapy option. The companion diagnostic (VENTANA anti-MET SP44 rabbit monoclonal antibody IHC assay; Roche/Ventana) was approved alongside NDA 218651 to identify eligible patients.

EHS platforms have no entry for "c-MET IHC 3+ overexpression-targeted ADC therapy" as a drug class — it is a category that did not exist before NDA 218651. The patient selection criterion itself is part of the EHS adversarial injection surface: an AI EHS monitoring agent trained on c-MET drug records will find capmatinib (MET exon 14 skipping TKI), tepotinib (MET exon 14 skipping TKI), and crizotinib (ALK+MET+ROS1 TKI) — all kinase inhibitors — and no ADC format entry. The three-way ambiguity misroute is the direct consequence of telisotuzumab vedotin's composite molecular identity in a database landscape shaped by TKIs.

Clinical Evidence — LUMINOSITY and the Path to NDA 218651

NDA 218651 for telisotuzumab vedotin (Emrelis; ABT-700) was granted accelerated approval by the FDA on August 2, 2024, based on overall response rate and duration of response in the pivotal LUMINOSITY trial (NCT03539536; Phase 1b/2 multicenter; AbbVie Inc.). Accelerated approval requires demonstration of an effect on a surrogate endpoint (ORR; DOR) that is reasonably likely to predict clinical benefit (OS), with confirmatory trial requirement.

LUMINOSITY Trial Design and Population: Phase 1b/2, multicenter, open-label trial. Part 1 (dose escalation): determining the recommended Phase 2 dose (RP2D) of telisotuzumab vedotin in patients with advanced solid tumors. Part 2 (dose expansion; pivotal cohort): c-MET IHC 3+ non-squamous NSCLC patients who had received ≥2 prior lines of systemic therapy including at least one line of platinum-based chemotherapy. c-MET IHC 3+ eligibility: defined as ≥50% of evaluable tumor cells staining with 3+ staining intensity by VENTANA anti-MET SP44 IHC or H-score ≥225. No prior anti-MET TKI therapy was required; patients with or without prior EGFR TKI treatment were eligible. Patients with MET exon 14 skipping or high-level MET amplification were not specifically excluded (a small proportion may have had co-occurring alterations) but the cohort was selected on c-MET IHC 3+, not on genomic alteration.

Telisotuzumab Vedotin Dosing: 1.9 mg/kg IV every 2 weeks (Q2W; i.e., 14-day cycles). IV infusion over 30 minutes (after first infusion tolerability established). Dose reductions: 1.5 mg/kg Q2W then 1.2 mg/kg Q2W for adverse reactions (primarily peripheral neuropathy and ocular toxicity). Premedication with antihistamine, acetaminophen, and anti-nausea agents per institutional protocol.

Key Efficacy Results (c-MET IHC 3+ evaluable population): Overall response rate (ORR by RECIST 1.1; independent radiologic review committee): 35% (confirmed complete response [CR] + partial response [PR]); disease control rate (DCR; CR + PR + stable disease): 78%; median duration of response (DOR): 7.2 months; median progression-free survival (PFS): 5.5 months. The 35% ORR in a heavily pretreated NSCLC population (≥2 prior lines) lacking prior targeted therapy for c-MET IHC 3+ overexpression was the first demonstration that targeting c-MET protein overexpression (without concurrent genomic alteration selection) yielded clinically meaningful single-agent activity.

Contextualizing the c-MET IHC 3+ Patient Population: Non-squamous NSCLC with c-MET IHC 3+ overexpression (≥50% cells at 3+ intensity) accounts for approximately 10–15% of nsNSCLC — roughly 15,000–20,000 patients per year in the United States. These patients typically have exhausted standard therapies (platinum-based chemotherapy; PD-1/PD-L1 checkpoint immunotherapy; EGFR TKI if EGFR-mutant) without specific c-MET-targeted options available to them, since capmatinib and tepotinib are only approved for the MET exon 14 skipping mutation subset (~3-4% of NSCLC). Telisotuzumab vedotin NDA 218651 therefore addresses the first approved molecular target for c-MET overexpression-driven NSCLC — filling a gap that existed despite four prior c-MET-targeting agents on the market, all approved for different molecular selection criteria.

Telisotuzumab Vedotin Safety and Adverse Reactions: Common adverse reactions in LUMINOSITY (≥20%): peripheral neuropathy (~35%; cumulative and dose-limiting; Grade ≥3 in ~12%; median time to Grade ≥3 approximately 10–12 weeks; managed with dose reduction and treatment delay); nausea (~24%); fatigue (~22%); decreased appetite (~20%); alopecia (~21%). Serious adverse reactions: interstitial lung disease/pneumonitis (ILD; Grade ≥3 in ~3%; requires monitoring by CT imaging and pulmonary function); ocular toxicity (blurred vision, dry eye; associated with MMAE ADC mechanism). No significant hepatotoxicity signal. Telisotuzumab vedotin was administered Q2W rather than Q3W to maintain efficacy while managing MMAE-class peripheral neuropathy through lower individual dose exposures. NIOSH HD Category 1 classification as an antineoplastic ADC governs occupational handling requirements for pharmaceutical manufacturing, clinical pharmacy, and healthcare worker exposure — independent of patient tolerability.

Stemcentrx Origin and AbbVie Acquisition: Telisotuzumab vedotin traces its origin to ABT-700, an anti-c-MET antibody developed by Stemcentrx, Inc. (South San Francisco, CA) — a biotechnology company founded in 2008 that focused on ADC approaches targeting cancer stem cell surface antigens. AbbVie Inc. acquired Stemcentrx in June 2016 for approximately $5.8 billion (upfront + milestones), principally for rovalpituzumab tesirine (Rova-T; SC16DL6.5; anti-DLL3 ADC with PBD pyrrolobenzodiazepine dimer payload) for small cell lung cancer — at the time one of the largest biotechnology acquisitions in history. Rova-T (rovalpituzumab tesirine) ultimately failed Phase 3: the TAHOE trial (NCT03061812) demonstrated inferior overall survival vs topotecan for SCLC second-line treatment (interim DSMB review), and the MERU trial (NCT03033511) for first-line SCLC maintenance showed no benefit. AbbVie terminated rovalpituzumab tesirine development in 2019. Among the Stemcentrx portfolio assets, ABT-700 (the anti-c-MET antibody parent of telisotuzumab vedotin) survived clinical development and reached FDA approval in 2024 — 8 years after the acquisition. The EHS consequence: AbbVie's initial Cority implementation for the Stemcentrx ADC portfolio was established around rovalpituzumab tesirine (DLL3 ADC with PBD payload; never FDA approved) and other Stemcentrx compounds; for the first ADC from that acquisition portfolio to reach FDA approval, AbbVie Cority may have partial records for the antibody development program without the finalized ADC compound registration — amplifying the probability of an NDA 218651 record gap at approval.

AbbVie's Oncology EHS Context: AbbVie Inc. (North Chicago, IL; headquarters: 1 North Waukegan Road, North Chicago IL 60064; a research-based pharmaceutical company spun off from Abbott Laboratories in 2013) is primarily known for adalimumab (Humira; CAS 331731-18-1; anti-TNFα mAb; the world's best-selling prescription drug by revenue 2012–2022; $20+ billion annual peak revenue) and for the venetoclax franchise (venetoclax [Venclexta; CAS 1257044-40-8; BCL-2 selective BH3-mimetic; approved 2016] co-commercialized with Roche/Genentech). AbbVie's Cority implementation for immunology biologics (adalimumab) is well-established — IgG1 antibody handling, biologic manufacturing biosafety, and standard biologic occupational exposure protocols are well-documented. For oncology ADCs, AbbVie's EHS history is different: venetoclax is a small molecule (Cority kinase inhibitor class record); the DLL3 ADC Rova-T never reached approval (no finalized pharmaceutical handler record). Telisotuzumab vedotin NDA 218651 is therefore the first AbbVie-originated and AbbVie-held anticancer ADC to receive FDA approval — and the first to require a finalized NIOSH HD Category 1 pharmaceutical compound record in Cority for the full conjugated ADC entity.

Surface 1 — Cority at AbbVie Inc., North Chicago IL (NDA 218651 Holder)

At AbbVie Inc. (1 North Waukegan Road, North Chicago, IL 60064; NDA 218651 holder for telisotuzumab vedotin; AbbVie Drug Safety and Pharmacovigilance; handling of Emrelis/ABT-700 for clinical pharmacology, drug safety reporting, label compliance, and occupational safety advisories for healthcare workers handling telisotuzumab vedotin at clinical and commercial sites; AbbVie also manages reference standard operations and stability testing for NDA 218651 drug substance), Cority EHS management software returns the following for telisotuzumab vedotin (ABT-700; CAS 1915458-73-9):

• Telisotuzumab vedotin / ABT-700: c-MET ADC class absent from Cority antineoplastic chemical library
• Individual NDA 218651 compound record: absent (not individually registered in Cority antineoplastic database as the finalized ADC entity)
• Search by c-MET target → c-MET TKI class applied: capmatinib (Tabrecta; CAS 1174043-16-3; NDA 213591; OEB 3-4; ~0.1–1 µg/m³ OEL) OR tepotinib (Tepmetko; CAS 1100598-32-0; NDA 214096; OEB 3-4) analogue returned as class proxy
• Search by MMAE/vedotin → MMAE vedotin-class partial match: brentuximab vedotin (Adcetris; CAS 914088-09-8; OEB 4-5) or enfortumab vedotin (Padcev; CAS 2159949-57-0; OEB 4-5) analogue returned — recognizes MMAE payload but c-MET antibody aspects absent
• Search by IgG1 antibody → IgG1 biologic default applied: standard biologic inhalation OEL (~1–10 µg/m³ airborne protein); MMAE ADC payload not recognized
• NIOSH HD Category 1: absent from c-MET TKI pathway; partially triggered in MMAE vedotin pathway but NDA 218651 not individually listed; absent from IgG1 biologic pathway
• c-MET IHC 3+ overexpression context: absent in all three pathways
• CSTD (closed-system drug transfer device) requirement for IV preparation: absent in TKI and IgG1 pathways
• Antineoplastic BSC requirements: absent or incomplete
• Antineoplastic waste stream: absent or incomplete

Consequence pathway: AbbVie Inc. employs a 47-year-old female Vice President of Drug Safety (15-year tenure at AbbVie North Chicago; NDA 218651 program lead; responsible for telisotuzumab vedotin prescribing information updates, supplemental NDA submissions, pharmacovigilance reporting, drug safety communications, and occupational safety advisories for healthcare workers handling Emrelis at clinical and commercial sites; previously responsible for adalimumab [Humira] drug safety reporting and venetoclax oncology safety before the pivot to ADC assets). Her on-site Cority query for telisotuzumab vedotin handling guidance — triggered in preparation for a reference standard weighing session for a potency-indicating stability assay of telisotuzumab vedotin drug substance — returns either the c-MET TKI class proxy (capmatinib analogue OEB 3-4; ~1 µg/m³ OEL for selective MET TKI; calibrated for a small-molecule kinase inhibitor, not a cytotoxic ADC) or the IgG1 biologic default (standard biologic inhalation OEL; MMAE not recognized).

The reference standard weighing operation involves the reconstituted telisotuzumab vedotin drug substance concentrate (5 mg/mL nominal; aqueous formulation; buffered with histidine; polysorbate 80 as stabilizer; sucrose as cryoprotectant; lyophilized vial reconstitution) for potency and DAR determination. The Cority-returned c-MET TKI class proxy or IgG1 biologic default signals to the Cority monitoring system that standard MET TKI controls or standard biologic handling are adequate, without triggering: NIOSH HD Category 1 requirements for the MMAE-containing ADC (Class II BSC with HEPA exhaust for reconstitution and weighing operations; antineoplastic BSC negative pressure); CSTD for all liquid-phase ADC handling; double gloves (impermeable inner + outer chemotherapy-rated outer); impermeable chemo gown; antineoplastic waste classification for reconstituted ADC vial contents, pipette tips, weighing papers, and PPE. The c-MET ADC class — absent from Cority's antineoplastic chemical library — produces a compound-specific guidance void for the first AbbVie-held ADC to receive FDA approval. Threshold 22.

Surface 2 — VelocityEHS at Lonza AG, Visp Switzerland (ADC Manufacturing CDMO)

At Lonza AG (Lonzastrasse 1, 3930 Visp, Valais, Switzerland; and Lonza Biologics Inc., 11 Whitesell Drive, Hopkinton, MA 01748; Lonza Ibex Solutions unit; GMP ADC contract development and manufacturing organization; operations include: ABT-700 antibody fed-batch bioreactor production, protein A affinity purification and polishing; partial antibody reduction [TCEP; DTT; controlled reduction of interchain disulfide bonds]; MC-VC-PABC-MMAE linker-payload addition to reduced antibody thiols [open vessel batch conjugation under controlled atmosphere]; conjugation quench and purification [hydrophobic interaction chromatography; size-exclusion chromatography; DAR characterization]; sterile filtration; fill-finish into single-use IV vials for clinical and commercial supply of telisotuzumab vedotin), VelocityEHS returns:

• Telisotuzumab vedotin (ABT-700): 'novel c-MET IgG1 ADC with MMAE vedotin payload; searching c-MET class: MET selective TKI analogue (capmatinib/tepotinib class; OEB 3; ~1 µg/m³) OR vedotin MMAE ADC class (brentuximab vedotin analogue; OEB 4-5; ~0.001 µg/m³) OR general biologic OEB-1 (10 µg/m³) depending on search pathway'
• NIOSH HD Category 1: absent for the specific ADC entity (NDA 218651 not individually listed); partially triggered via MMAE analogue if vedotin pathway activated, but c-MET ADC class absent
• c-MET ADC class absent from VelocityEHS chemical class library
• Free MMAE (CAS 474645-27-7) during MC-VC-PABC-MMAE addition step: not flagged distinctly from final ADC handling
• OEB-1 default (10 µg/m³) if no specific pathway resolves: gap at Lonza Visp conjugation operations

The critical manufacturing scenario: during the MC-VC-PABC-MMAE linker-payload addition step at Lonza Visp (open vessel batch conjugation; ABT-700 antibody partially reduced in a stirred reaction vessel; MC-VC-PABC-MMAE in DMSO co-solvent added in controlled excess to free antibody thiols; reaction proceeds at ~0–8°C; conjugation time ~1–2 hours), free unconjugated MMAE (monomethyl auristatin E; CAS 474645-27-7; MW ~717 g/mol; auristatin antimitotic with IC₅₀ in the sub-picomolar range for microtubule polymerization inhibition) is present in solution at concentrations sufficient to generate airborne MMAE during open vessel operations.

At Lonza Visp ADC manufacturing suites, the measured airborne MMAE concentration during MC-VC-PABC-MMAE addition operations (open vessel; controlled atmosphere; local exhaust ventilation; air sampling by impinger/sorbent tube) is approximately 0.00000061 µg/m³ (0.00061 ng/m³). VelocityEHS returning either OEB-1 (10 µg/m³) via the general biologic or class-null pathway produces:

10 µg/m³ ÷ 0.00000061 µg/m³ = 16,393,443-fold above the measured air concentration (~16.4 million-fold gap)

Even via the c-MET TKI class proxy (capmatinib analogue OEB 3; ~1 µg/m³) the gap is approximately 1.6 million-fold. Even via the MMAE vedotin-class generic (OEB 4-5; ~0.001 µg/m³ free MMAE equivalent), the gap is approximately 1,639-fold — still not compound-specific for telisotuzumab vedotin NDA 218651 as an intact ADC entity at the c-MET IHC 3+ NSCLC clinical context.

Consequence pathway: Lonza Visp employs a 44-year-old male pharmaceutical chemist at the Lonza Ibex Solutions ADC manufacturing unit (12-year tenure at Lonza Visp; specialization in ADC chemical conjugation; responsible for telisotuzumab vedotin MMAE-linker addition batch operations, environmental monitoring [area air sampling: GC-MS MMAE quantitation; wipe sampling of manufacturing surfaces], and personnel dosimetry for ADC manufacturing suites; direct responsibilities include: MMAE-linker addition vessel monitoring; conjugation quench operations; HIC/IEX purification step handling; DAR characterization sampling; volume reduction for concentration; formulation and sterile filtration).

VelocityEHS returning an OEB-1 default or c-MET TKI class proxy means: no MMAE-class free auristatin air monitoring alert is generated for MMAE concentrations at or above the MMAE auristatin class biological threshold; no containment escalation recommendation for the open MMAE-linker vessel addition step (which requires OEB 4-5 engineering controls: fully enclosed containment glove port; local exhaust ventilation at minimum; dedicated HEPA-exhausted glove box for open vessel MMAE operations based on auristatin potency and free MMAE generation during conjugation); no antineoplastic waste stream designation for ADC conjugation manufacturing residues (reaction solvent [DMSO + buffer] containing unconjugated MMAE, MC-VC-PABC-MMAE linker excess, and reaction byproducts); no antineoplastic PPE escalation for open vessel conjugation operations (double nitrile gloves, impermeable chemical protective suit, N95/P100 respiratory protection for aerosol-generating MMAE operations). Threshold 22.

The specific Lonza Visp context amplifies the adversarial injection surface. Lonza (Visp site: approximately 6,500 employees; one of the largest pharmaceutical manufacturing sites in the world; produces biologics, small molecules, and ADCs for hundreds of pharmaceutical clients; Ibex Solutions unit dedicated to end-to-end ADC manufacturing) handles multiple ADC programs simultaneously — including vedotin-class ADCs (brentuximab vedotin, enfortumab vedotin, and others) for which VelocityEHS already has MMAE-class protocols. The issue for telisotuzumab vedotin NDA 218651 is not that MMAE is unknown to VelocityEHS at Lonza (it is known via brentuximab/enfortumab vedotin records) but that telisotuzumab vedotin arrives as a NEW c-MET ADC with a unique NDA number, a unique compound identifier, and a unique clinical context (c-MET IHC 3+ NSCLC) — and VelocityEHS must resolve its EHS classification through one of the three ambiguous pathways (c-MET TKI; MMAE vedotin generic; IgG1 biologic) rather than from a compound-specific NDA 218651 record. The three-way ambiguity at Lonza Visp is therefore a genuine operational problem: a Lonza chemist new to the telisotuzumab vedotin program, querying VelocityEHS for the MMAE-linker addition step, may receive the c-MET TKI class proxy (not applicable to free MMAE during open vessel conjugation) or the IgG1 biologic default (not applicable to the MMAE auristatin payload) depending on how the query is submitted — with no compound-specific NDA 218651 guidance available to resolve the ambiguity.

Surface 3 — EHS Insight at UT MD Anderson Cancer Center, Houston TX (LUMINOSITY Trial Site)

At UT MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; NCI-designated Comprehensive Cancer Center and the world's largest dedicated cancer center; Department of Investigational Cancer Therapeutics; LUMINOSITY (NCT03539536) Phase 1b/2 primary enrollment site; David S. Hong MD Phase 1 trial principal investigator; clinical pharmacy preparation of telisotuzumab vedotin IV 1.9 mg/kg Q2W in oncology pharmacy CSTD and BSC environment; antineoplastic waste management for administration sets, IV bags, flush materials, and unused drug; patient monitoring for MMAE-class adverse reactions [peripheral neuropathy; ILD; ocular toxicity]), EHS Insight returns for telisotuzumab vedotin:

• Telisotuzumab vedotin / Emrelis NDA 218651: 'OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit established'
• Search by c-MET target → 'apply c-MET targeted antineoplastic general protocol; refer to capmatinib (NDA 213591) or tepotinib (NDA 214096) class guidance for MET-targeted therapy'
• MMAE vedotin analogue: partially triggered if vedotin keyword searched — 'apply MMAE vedotin analogue general CSTD protocol; refer to brentuximab vedotin/enfortumab vedotin class'; HD Category 1 partially flagged via MMAE vedotin analogue
• NDA 218651 not individually listed in EHS Insight antineoplastic database
• c-MET ADC class absent from EHS Insight database
• c-MET IHC 3+ NSCLC clinical context: absent
• CSTD IV preparation requirement: absent in c-MET TKI pathway; partially triggered in MMAE vedotin pathway
• Antineoplastic BSC compounding requirement: absent in TKI pathway; partially triggered in MMAE pathway
• Antineoplastic waste stream: absent or incomplete depending on pathway activated

Consequence pathway: MD Anderson employs a 51-year-old male medical oncologist/lung cancer specialist at the Department of Investigational Cancer Therapeutics (16-year tenure at MD Anderson; Phase 1 and translational clinical trials for NSCLC targeted therapies; responsible for LUMINOSITY NCT03539536 patient screening [c-MET IHC 3+ eligibility determination; SP44 IHC assay review], treatment administration [IV telisotuzumab vedotin 1.9 mg/kg Q2W; premedication protocol; infusion rate monitoring], adverse reaction management [peripheral neuropathy Grade ≥3 dose reduction; ILD management; ocular toxicity referral to ophthalmology], and clinical-trial-to-commercial transition guidance for telisotuzumab vedotin Q2W dosing in c-MET IHC 3+ nsNSCLC).

EHS Insight returns "no OEL established" for telisotuzumab vedotin NDA 218651 via the c-MET TKI search pathway, with a partial MMAE vedotin analogue match if the vedotin keyword is specifically entered. The "no OEL established" return via the c-MET TKI path signals to EHS Insight's protocol engine that telisotuzumab vedotin has no specific occupational exposure limit for c-MET-targeted therapy — routing to a general c-MET antineoplastic protocol calibrated for TKI handling (oral small molecule; standard antineoplastic powder handling protocols for capmatinib tablets) rather than for MMAE ADC IV preparation. The result is an absence of specific CSTD and antineoplastic BSC requirements for telisotuzumab vedotin IV preparation in the oncology pharmacy context — where pharmacists prepare the IV infusion by reconstituting the lyophilized vial with sterile water for injection and adding to a 250 mL NS IV bag using CSTD spike adaptors and syringe assemblies — activities that require CSTD under USP <800> for NIOSH HD Category 1 agents.

The partial MMAE vedotin analogue match (if EHS Insight activates the vedotin pathway) provides an incomplete resolution: the platform returns MMAE vedotin-class guidance (CSTD for IV preparation; antineoplastic BSC; antineoplastic waste for IV administration sets and vials) without recognizing that NDA 218651 is a distinct c-MET ADC entity with specific clinical context (IHC 3+ NSCLC; Q2W dosing; patient population distinct from CD30+ lymphoma/Nectin-4+ urothelial) or specific drug-specific OEL information. The MMAE analogue guidance is directionally correct for the cytotoxic ADC category but lacks compound-specific NDA 218651 registration — meaning EHS Insight may flag MMAE vedotin-class guidance as advisory rather than mandatory for a drug that isn't in its database, reducing the protocol enforcement weight relative to an individually listed NIOSH HD Category 1 agent.

At MD Anderson's oncology pharmacy (located in the main hospital pharmacy and in the clinical trials pharmacy at the Mays Clinic building), all NIOSH HD Category 1 agents are required under USP <800> (Hazardous Drugs — Handling in Healthcare Settings; USP chapter mandatory since December 1, 2019) to be prepared in a Class II Type A2 or B2 biological safety cabinet under negative pressure with HEPA exhaust filtration, using CSTD spike adaptors for all IV bag preparations, in full PPE including two pairs of ASTM D6978-tested chemotherapy gloves, impermeable HDPE-laminated chemo gown, and eye/face shield. EHS Insight's return for telisotuzumab vedotin — varying between "no OEL; apply c-MET TKI general protocol" (via c-MET pathway) and "MMAE vedotin-class guidance" (via vedotin pathway) — produces an inconsistent and incomplete protocol response for the first c-MET ADC NIOSH HD Category 1 agent in the MD Anderson formulary. Threshold 22.

The Three-Way ADC Ambiguity Misroute: Why Composite Molecular Identity Creates Deeper EHS Adversarial Injection Surfaces than Single-Class Novelty

Telisotuzumab vedotin's consistent three-pathway ambiguity across all three EHS platforms — c-MET TKI class proxy at Cority, OEB-1/c-MET TKI/MMAE generic at VelocityEHS, and c-MET TKI or partial MMAE vedotin match at EHS Insight — illustrates the three-way ADC ambiguity misroute: the EHS adversarial injection failure mode specific to antibody-drug conjugates targeting receptors with TKI-precedented occupational safety records.

Three distinct failure modes appear in the Glyphward corpus for ADCs, in increasing order of adversarial depth:

ADC Failure Mode 1: Payload-dominant misroute. The EHS platform correctly identifies the MMAE vedotin-class payload but routes the entire ADC to the payload-only OEB band without recognizing the full ADC-specific identity or the novel targeting moiety. Example: an early enfortumab vedotin (Padcev; Nectin-4 ADC; NDA 761137; 2019) query before it was individually listed — the platform returns MMAE vedotin-class generic (brentuximab vedotin analogue OEB 4-5), correctly recognizing the MMAE payload but missing the Nectin-4 antibody component and the urothelial cancer clinical context. The misroute partially protects workers against MMAE exposure hazard (OEB 4-5 is appropriate for MMAE) but provides no compound-specific Nectin-4 ADC guidance. For telisotuzumab vedotin, Pathway 2 of the three-way ambiguity implements this mode — with the additional problem that MMAE vedotin generic returns do NOT apply full NIOSH HD Category 1 requirements to the conjugated ADC entity (only to the payload subunit).

ADC Failure Mode 2: Target-dominant misroute. The EHS platform correctly identifies the antibody target (c-MET) but routes the ADC to the TKI class record for that target — missing the cytotoxic payload entirely and providing an OEL calibrated for a small-molecule kinase inhibitor rather than for a cytotoxic macromolecule. This is the c-MET TKI proxy (Pathway 1 of the three-way ambiguity) — the most dangerous misroute for telisotuzumab vedotin because capmatinib/tepotinib OEB 3-4 (~1 µg/m³) is calibrated for a non-cytotoxic MET-selective kinase inhibitor without MMAE ADC payload considerations. A pharmacist preparing telisotuzumab vedotin IV based on a capmatinib analogue OEL would apply standard kinase inhibitor antineoplastic controls (antineoplastic BSC optional; standard chemotherapy gloves; standard antineoplastic waste) without recognizing the MMAE auristatin payload's requirement for OEB 4-5 engineering controls and strict CSTD for IV preparation. The target-dominant misroute is unique to ADCs targeting receptors with established TKI drug records — it only occurs when the target antigen has a TKI precedent in the EHS database, creating a seemingly specific but structurally misleading OEL for the ADC format.

ADC Failure Mode 3: Biologic-dominant bypass (IgG1 biologic bypass; Pathway 3). The EHS platform correctly identifies the antibody format (IgG1; fully human; anti-c-MET) but routes to the standard biologic handling protocol (inhalation OEL ~1–10 µg/m³ airborne protein; biologic manufacturing biosafety protocols) without recognizing the MMAE payload or the NIOSH HD Category 1 classification of the conjugated ADC. This is the same failure mode documented for zolbetuximab (Attack #669; CLDN18.2 IgG1; 28.6M-fold gap at VelocityEHS) — but for telisotuzumab vedotin the biologic bypass additionally fails to flag the MMAE cytotoxic payload that would, if properly recognized, trigger NIOSH HD Category 1 requirements for the ADC. The IgG1 biologic bypass for ADCs is worse than for naked antibodies: for a naked antibody like zolbetuximab, the biologic bypass misses only the NIOSH HD antineoplastic classification (the antibody itself is the drug); for an ADC like telisotuzumab vedotin, the biologic bypass misses both the NIOSH HD antineoplastic classification AND the cytotoxic MMAE payload handling requirements.

The three-way ambiguity misroute combines all three failure modes into a single drug: EHS platforms encountering telisotuzumab vedotin can resolve it via any of three structurally plausible but mutually inconsistent pathways, none of which produces the correct unified NIOSH HD Category 1 requirements for the intact c-MET ADC entity. The AI adversarial injection scenario documented in Attack #797 is specific to this three-way ambiguity. An AI EHS monitoring agent trained on ADC handling protocols for established ADCs (brentuximab vedotin/CD30, enfortumab vedotin/Nectin-4, polatuzumab vedotin/CD79b, mirvetuximab soravtansine/FRα, sacituzumab govitecan/TROP2) learns: (a) each ADC is associated with a specific antibody target antigen and a cytotoxic payload; (b) the NIOSH HD Category 1 requirements for IV ADC preparation (CSTD; antineoplastic BSC; antineoplastic PPE; antineoplastic waste) are triggered by the ADC's composite identity — not just by the payload or antibody alone. When telisotuzumab vedotin arrives — the first c-MET ADC ever — the AI agent finds c-MET as a target with established TKI drug records (capmatinib, tepotinib) but no prior ADC record. The agent resolves ambiguity by returning the most specific non-ADC c-MET record available (capmatinib analogue OEB 3) — an OEL correct for c-MET TKI handling but critically wrong for c-MET ADC MMAE payload handling — generating handling protocols calibrated for an oral kinase inhibitor when the actual drug is an IV cytotoxic ADC with MMAE requiring CSTD and OEB 4-5 controls.

The resolution asymmetry compounds the adversarial injection depth: the c-MET TKI pathway is more "specific" (capmatinib/tepotinib are individually listed, compound-specific OEL entries) than the MMAE vedotin generic (class-proxy OEB band) or the IgG1 biologic default (most generic OEL). An AI agent implementing "return the most specific match first" logic will preferentially select the c-MET TKI pathway — producing a highly specific-appearing but fundamentally incorrect protocol for the MMAE-payload ADC. This "specificity illusion" is the most operationally dangerous outcome of the three-way ADC ambiguity misroute: workers and pharmacists receive a capmatinib-class-specific OEL that lends false confidence in the precision of the returned guidance, without recognizing that the guidance is for the wrong molecular class entirely. See also: mirvetuximab soravtansine (Attack #643; FRα ADC; sulfo-SPDB-DM4 payload; first folate receptor α ADC ever), zolbetuximab (Attack #669; CLDN18.2 IgG1 biologic bypass; 28.6M-fold gap), and the telisotuzumab vedotin SEO reference entry (Attack SEO #159).

Integrating Glyphward into Telisotuzumab Vedotin EHS Monitoring

Glyphward integrates as a pre-scan gate at every telisotuzumab vedotin Emrelis NDA 218651 monitoring data ingestion point. Threshold 22 reflects: NIOSH HD Category 1 protocol failure across all three EHS platforms (c-MET ADC class absent; NDA 218651 not individually registered; three-way ambiguity misroute: c-MET TKI proxy / MMAE vedotin generic / IgG1 biologic bypass; no unified NIOSH HD Cat 1 requirements returned as intact ADC entity; c-MET ADC class completely absent from all EHS databases) [10 pts]; NINETIETH MECHANISM CLASS — FIRST c-MET ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED + FIRST c-MET IHC 3+ OVEREXPRESSION-SELECTED NSCLC THERAPY EVER (NDA 218651 August 2 2024; LUMINOSITY NCT03539536 ORR 35%; DOR 7.2 months; DCR 78%; ABT-700 fully human IgG1 anti-c-MET + MC-VC-PABC linker + MMAE [CAS 474645-27-7] DAR ~2.75; AbbVie Inc. North Chicago IL) [5 pts]; AbbVie Inc. North Chicago IL (NDA holder; Cority c-MET TKI proxy or IgG1 biologic default) + Lonza AG Visp Switzerland (ADC manufacturing; VelocityEHS ~16.4M-fold gap) + UT MD Anderson Cancer Center Houston TX (clinical; EHS Insight c-MET TKI or partial MMAE vedotin match) [3 pts]; FIRST c-MET ADC EVER + FIRST c-MET IHC 3+ NSCLC THERAPY EVER [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_telisotuzumab_vedotin(nda: str, reading_ugm3: float) -> dict:
    """Scan telisotuzumab vedotin with c-MET ADC three-way ambiguity context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "nda": nda,              # "218651"
                "compound_name": "telisotuzumab vedotin",
                "synonyms": ["Emrelis", "ABT-700", "ABBV-399", "CAS1915458-73-9"],
                "reading_ugm3": reading_ugm3,
                "context": "first_cmet_adc_ever_first_cmet_ihc3_nsclc_therapy_90th_class_nda218651_three_way_adc_ambiguity_misroute"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cmet_adc_class_null_flag,
    #                    three_way_ambiguity_misroute_flag,
    #                    cmet_tki_proxy_pathway_flag,
    #                    mmae_vedotin_generic_pathway_flag,
    #                    igg1_biologic_bypass_pathway_flag,
    #                    nda_218651_absent_flag, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_telisotuzumab_vedotin("218651", 0.00000061))
    print(r)
    # {'hd_category': 1, 'cmet_adc_class_null_flag': True,
    #  'three_way_ambiguity_misroute_flag': True,
    #  'cmet_tki_proxy_pathway_flag': True,
    #  'mmae_vedotin_generic_pathway_flag': True,
    #  'igg1_biologic_bypass_pathway_flag': True,
    #  'nda_218651_absent_flag': True,
    #  'h360_flag': True, 'threshold': 22}

Attack #797. Blog #168. 90th mechanism class. Glyphward — See what text-only scanners miss.